

Datasheet: HCA061

Description:	HUMAN ANTI RITUXIMAB
Specificity:	RITUXIMAB
Other names:	MabThera®, Rituxan®
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD02842
Isotype:	HuCAL Fab bivalent
Quantity:	0.1 mg

Product Details

RRID AB_915387

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			1/100

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

A bivalent human recombinant Fab (lambda light chain) selected from the HuCAL® GOLD phage display library. Expressed in E. coli and purified using metal chelate affinity chromatography. This Fab fragment is dimerized via a helix-turn-helix motif. The antibody is tagged with a myc-tag (EQKLISEEDL) and a his-tag (HHHHHH) at the C-terminus of the antibody heavy chain - liquid.

Preparation

Metal chelate affinity chromatography

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml.

Immunogen

Rituximab

Specificity

Human Anti-Rituximab Antibody, clone AbD02842, is a recombinant, anti-idiotypic antibody in bivalent Fab format that specifically recognizes the monoclonal antibody drug rituximab and inhibits it binding to its target, CD20. The antibody can be used to measure the levels of rituximab and biosimilar products in bioanalytical assays.

Rituximab (reference product branded as Rituxan) is a chimeric mouse/human monoclonal antibody approved for the treatment of certain autoimmune diseases and cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. The antibody is specific for the cell surface protein CD20, which is widely expressed on B cells. Through three different mechanisms of action it eliminates B cells from the body, enabling the development of a new population of healthy B cells.

[View a summary of all anti-rituximab antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D=4.9$ nM by real time, label-free molecular interaction analysis on immobilized Rituximab.
ELISA	In its HRP conjugated format (HCA061P), this product may be used as a detection reagent in a sandwich ELISA. Protocol: PK bridging ELISA to measure free drug.
References	1. Warncke, M. <i>et al.</i> (2012) Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J Immunol. 188: 4405-11.
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch.
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Rituxan® is a registered trademark of Biogen Idec/Genentech in the USA. MabThera® is a registered trademark of Roche in Europe. His-tag is a registered trademark of EMD Biosciences.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Secondary Antibodies

Mouse Anti Synthetic Peptide HISTIDINE TAG (MCA5995...) [HRP](#)

Goat Anti Human IgG F(ab')₂ (0500-0099...) [HRP](#)

Mouse Anti Human C-MYC (MCA2200...)

[HRP](#)

Recommended Useful Reagents

[HUMAN ANTI RITUXIMAB:HRP \(HCA062P\)](#)

[RAT ANTI RITUXIMAB \(MCA2260\)](#)

[RAT ANTI RITUXIMAB:FITC \(MCA2260F\)](#)

[HUMAN ANTI RITUXIMAB \(HCA186\)](#)

North & South America Tel: +1 800 265 7376
Fax: +1 919 878 3751
Email: antibody_sales_us@bio-rad.com

Worldwide Tel: +44 (0)1865 852 700
Fax: +44 (0)1865 852 739
Email: antibody_sales_uk@bio-rad.com

Europe Tel: +49 (0) 89 8090 95 21
Fax: +49 (0) 89 8090 95 50
Email: antibody_sales_de@bio-rad.com

'M335087:181204'

Printed on 20 May 2019

© 2019 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)